An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Gilead Joins First-of-its-Kind Public-Private Initiative to Improve Management of Viral Hepatitis in Vietnam and the Philippines
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Positive)
Tags
Rhea-AI Summary
Gilead Sciences has launched a multi-year, public-private initiative in collaboration with the Partnership for Health Advancement in Vietnam (HAIVN) to enhance hepatitis care and management in Vietnam and the Philippines. This program aims to integrate hepatitis B and C diagnosis and treatment into primary healthcare, addressing barriers to access. With significant hepatitis prevalence in both countries, the initiative aligns with WHO targets for viral hepatitis elimination by 2030, hoping to strengthen healthcare systems and broaden patient access to care.
Positive
Initiative supports WHO targets for viral hepatitis elimination by 2030.
Addresses significant barriers to diagnosis and treatment in Vietnam and the Philippines.
Aims to strengthen primary healthcare systems and enhance patient access.
Negative
Current pace suggests Vietnam and the Philippines may not meet WHO targets before 2050.
Limited implementation of best practices and access to treatment reported.
- Public-Private Effort to Shift Traditional Model of Hepatitis Management to Primary Care and Help to Expand Care to More People in Need -
FOSTER CITY, Calif.--(BUSINESS WIRE)--
Gilead Sciences, Inc. today announced a new public-private initiative with the Partnership for Health Advancement in Vietnam (HAIVN), a collaboration between Brigham and Women’s Hospital, Harvard Medical School and Beth Israel Deaconess Medical Center. This multi-year initiative will have a phased approach to help address barriers that limit viral hepatitis diagnosis and care at primary healthcare facilities in Vietnam and the Philippines, two countries with high burdens of hepatitis B and C.
Gilead and HAIVN will work together with a multi-stakeholder coalition, involving national ministries of health, academic stakeholders including the University of Philippines-Manila (UP Manila), provincial hospitals and primary healthcare centers to support this pilot program. The focus of the program will be on person-centered approaches in training non-specialist community-based healthcare providers in prevention and management of viral hepatitis, incorporating education, screening, diagnosis and linkage to care for hepatitis B and C into routine patient visits for at-risk populations. Gilead and HAIVN will also aim to strengthen primary healthcare systems including the referrals and counter-referral systems to enhance coordination between specialist and primary care. The two organizations will make the outcomes and learnings from the initiative public to contribute towards better understanding of adequate public health approaches to improve person-centered, community-based management of viral hepatitis.
“This collaboration will provide evidence to support a shift from the current dependence on scarce and overstretched specialists to a broader group of primary care clinicians while simultaneously strengthening primary health care systems and expanding countries’ capacity to diagnose, manage and treat viral hepatitis,” said David Duong, MD, MPH, Director of the Harvard Medical School Program in Global Primary Care and Social Change and an internal medicine physician at Brigham and Women’s Hospital. “Through this innovative initiative with Gilead, we will apply new patient-centered, community-based models to hepatitis care and treatment, building on the foundation that HAIVN has built.”
The initiative will support national priorities for Vietnam and the Philippines: both governments are committed to strengthening primary healthcare and controlling hepatitis. The World Health Organization has set a global target to eliminate viral hepatitis as a public health problem by 2030, calling for 90% of people with hepatitis B and C to be diagnosed, 80% of those eligible for treatment to be treated and a 65% reduction in mortality, in addition to developing preventative actions.1 However, despite the important gains in biomedical technology and management of viral hepatitis, implementation of best practices and access to diagnostics and treatment in both countries are still significantly limited and inconsistent. At the current pace, Vietnam and the Philippines are not expected to reach WHO targets before 2050.
“This approach has significant potential for application in many other disease areas and low- and middle-income countries where specialist providers are scarce,” said Dr. Harald Nusser, Vice President, Head of Global Patient Solutions, Gilead Sciences. “More than proof of concept for eliminating viral hepatitis and strengthening healthcare systems, this initiative demonstrates the potential for the meaningful impact that public, private and academic collaborations can make on improving global health equity and achieving Sustainable Development Goal 3 regarding good health and well-being.”
Hepatitis B and C lead to chronic disease in hundreds of millions of people globally and together are the most common cause of liver cirrhosis, liver cancer and viral hepatitis-related deaths. An estimated 354 million people worldwide live with hepatitis B or C, and for most, testing and treatment remain beyond reach.2 In Vietnam, out of a population of 97 million, nearly 7.8 million people have hepatitis B and over 900,000 have hepatitis C. Based on 2020 estimates from the CDA Foundation’s Polaris database, only 30% of Vietnamese people with hepatitis B have been diagnosed and only 3% treated. For hepatitis C, only 14% of cases have been diagnosed and 7% have been treated.3 In the Philippines, over 10 million people are infected with hepatitis B and nearly 450,000 with hepatitis C, with the care cascade standing at 5% diagnosed and less than 1% treated for hepatitis B and 23% diagnosed and 1% treated for hepatitis C. 3
About Sustainable Development Goals
The 17 Sustainable Development Goals (SDG) were adopted by the United Nations (UN) Member States in 2015, as part of the 2030 Agenda for Sustainable Development. They are call to actions by all countries to unite in a global partnership to ensure peace and prosperity for people and planet. SDG 3 Good Health and Wellbeing is one of the SDGs that Gilead supports to improve global health and sustainable development. SDG 3 consists of several targets, including fighting communicable diseases, achieving universal health coverage, increasing health financing and support for health workforce in developing countries. For more information on the SDGs that Gilead support, please visit www.gilead.com.
About Gilead Sciences
Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis and cancer. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California.
Gilead and the Gilead logo are trademarks of Gilead Sciences, Inc., or its related companies.
For more information about Gilead, please visit the company’s website at www.gilead.com, follow Gilead on Twitter (@Gilead Sciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.
What is Gilead Sciences' new initiative related to hepatitis?
Gilead Sciences announced a public-private initiative with HAIVN to improve hepatitis B and C diagnosis and care at primary healthcare facilities in Vietnam and the Philippines.
What are the goals of the hepatitis initiative by Gilead Sciences?
The initiative aims to integrate hepatitis care into primary healthcare and support WHO targets for elimination of viral hepatitis by 2030.
How many people are affected by hepatitis B and C in Vietnam?
In Vietnam, approximately 7.8 million people have hepatitis B and over 900,000 have hepatitis C.
What challenges does Gilead's initiative aim to address?
The initiative seeks to overcome barriers limiting hepatitis diagnosis and treatment in Vietnam and the Philippines, where healthcare access is often inconsistent.
What is the expected timeline for achieving WHO targets in Vietnam and the Philippines?
At the current pace, Vietnam and the Philippines are not expected to achieve WHO targets before 2050.
